Global Preimplantation Genetic Testing Market to Reach $1.3 Billion by 2030
The global market for Preimplantation Genetic Testing estimated at US$446.8 Million in the year 2022, is projected to reach a revised size of US$1.3 Billion by 2030, growing at a CAGR of 14.7% over the analysis period 2022-2030. Reagents & Consumables, one of the segments analyzed in the report, is projected to record 15.6% CAGR and reach US$716.4 Million by the end of the analysis period. Taking into account the ongoing post pandemic recovery, growth in the Instruments segment is readjusted to a revised 13.3% CAGR for the next 8-year period.The U.S. Market is Estimated at $130.7 Million, While China is Forecast to Grow at 13.8% CAGR
The Preimplantation Genetic Testing market in the U.S. is estimated at US$130.7 Million in the year 2022. China, the world's second largest economy, is forecast to reach a projected market size of US$226.9 Million by the year 2030 trailing a CAGR of 13.8% over the analysis period 2022 to 2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at 13.7% and 12.2% respectively over the 2022-2030 period. Within Europe, Germany is forecast to grow at approximately 12.1% CAGR.Select Competitors (Total 34 Featured) -
- Ariosa Diagnostics
- Bioarray S.L.
- California Pacific Medical Center (CPMC)
- CombiMatrix
- CooperSurgical, Inc.
- F. Hoffmann-La Roche Ltd.
- Genea Limited
- Genesis Genetics
- Good Start Genetics, Inc.
- IGENOMIX
- Illumina, Inc.
- Invitae Corporation
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Oxford Gene Technology
- PerkinElmer Inc.
- Quest Diagnostics Incorporated
- Reproductive Genetic Innovations, LLC
- Reprogenetics
- RHS Ltd.
- Sequenom
- Thermo Fisher Scientific, Inc.
What's New?
- Special coverage on Russia-Ukraine war; global inflation; easing of zero-Covid policy in China and its 'bumpy' reopening; supply chain disruptions, global trade tensions; and risk of recession.
- Global competitiveness and key competitor percentage market shares
- Market presence across multiple geographies - Strong/Active/Niche/Trivial
- Online interactive peer-to-peer collaborative bespoke updates
- Access to digital archives and Research Platform
- Complimentary updates for one year
Table of Contents
I. METHODOLOGYII. EXECUTIVE SUMMARY2. FOCUS ON SELECT PLAYERS3. MARKET TRENDS & DRIVERSIII. MARKET ANALYSISCANADAITALYREST OF EUROPEREST OF WORLDIV. COMPETITION
1. MARKET OVERVIEW
4. GLOBAL MARKET PERSPECTIVE
UNITED STATES
JAPAN
CHINA
EUROPE
FRANCE
GERMANY
UNITED KINGDOM
ASIA-PACIFIC
Companies Mentioned (Partial List)
A selection of companies mentioned in this report includes, but is not limited to:
- Ariosa Diagnostics
- Bioarray S.L.
- California Pacific Medical Center (CPMC)
- CombiMatrix
- CooperSurgical, Inc.
- F. Hoffmann-La Roche Ltd.
- Genea Limited
- Genesis Genetics
- Good Start Genetics, Inc.
- IGENOMIX
- Illumina, Inc.
- Invitae Corporation
- Laboratory Corporation of America Holdings
- Natera, Inc.
- Oxford Gene Technology
- PerkinElmer Inc.
- Quest Diagnostics Incorporated
- Reproductive Genetic Innovations, LLC
- Reprogenetics
- RHS Ltd.
- Sequenom
- Thermo Fisher Scientific, Inc.
Table Information
Report Attribute | Details |
---|---|
No. of Pages | 89 |
Published | April 2024 |
Forecast Period | 2022 - 2030 |
Estimated Market Value ( USD | $ 446.8 Million |
Forecasted Market Value ( USD | $ 1300 Million |
Compound Annual Growth Rate | 14.3% |
Regions Covered | Global |